You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
McKinsey
Dow
Johnson and Johnson
Mallinckrodt

Last Updated: February 27, 2021

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020823

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

NDA 020823 describes EXELON, which is a drug marketed by Novartis and is included in three NDAs. It is available from two suppliers. Additional details are available on the EXELON profile page.

The generic ingredient in EXELON is rivastigmine. There are thirty-two drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the rivastigmine profile page.
Summary for 020823
Tradename:EXELON
Applicant:Novartis
Ingredient:rivastigmine tartrate
Patents:0
Formulation / Manufacturing:see details
Paragraph IV (Patent) Challenges for 020823
Tradename Dosage Ingredient NDA Submissiondate
EXELON CAPSULE;ORAL rivastigmine tartrate 020823 2004-04-21

Profile for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:CAPSULE;ORALStrengthEQ 1.5MG BASE
Approval Date:Apr 21, 2000TE:RLD:Yes

Profile for product number 004

Active Rx/OTC/Discontinued:DISCNDosage:CAPSULE;ORALStrengthEQ 3MG BASE
Approval Date:Apr 21, 2000TE:RLD:Yes

Profile for product number 005

Active Rx/OTC/Discontinued:DISCNDosage:CAPSULE;ORALStrengthEQ 4.5MG BASE
Approval Date:Apr 21, 2000TE:RLD:Yes

Expired US Patents for NDA 020823

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis EXELON rivastigmine tartrate CAPSULE;ORAL 020823-003 Apr 21, 2000   Start Trial   Start Trial
Novartis EXELON rivastigmine tartrate CAPSULE;ORAL 020823-004 Apr 21, 2000   Start Trial   Start Trial
Novartis EXELON rivastigmine tartrate CAPSULE;ORAL 020823-005 Apr 21, 2000   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Mallinckrodt
Moodys
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.